All Picks
Every pick with full AI analysis, catalyst research, and actionable signals.
Portfolio Value
$10,082
Total Return
+0.82%
Win Rate
11%
Avg Return
-10.3%
Active Positions
Avg: +10.95%Closed Positions
| Ticker | Entry | Exit | P&L |
|---|---|---|---|
| DOCN | $89.90 | $75.61 | -15.90% |
| MRVL | $86.90 | $114.45 | +31.70% |
| EQT | $67.55 | $59.70 | -11.62% |
| NTLA | $15.44 | $12.37 | -19.88% |
| RKLB | $71.93 | $60.93 | -15.29% |
| VCYT | $36.02 | $30.01 | -16.67% |
| GE | $342.26 | $282.81 | -17.37% |
| LLY | $1051.99 | $878.24 | -16.52% |
| TSM | $366.99 | $326.74 | -10.97% |
Pick Archive
TSM Earnings Eve: The $400 Question Mark
Will Taiwan Semiconductor's earnings tomorrow justify analysts' sky-high $439 price target, or is this chip giant's 160% rally from $145 finally hitting a wall at $377?
GE's $190B Backlog Sets Up Perfect Pre-Earnings Play
With GE Aerospace's massive $190 billion backlog fueling expectations and earnings just 6 days away, this pullback from 52-week highs might be the perfect entry point for a pre-earnings momentum play.
Taiwan Semi: Wait for the Earnings Dip Before Loading Up
Despite Taiwan Semi's blistering 45% YoY sales growth and proximity to 52-week highs, savvy investors should resist FOMO and wait for the inevitable post-earnings volatility to create a better entry point in this chip powerhouse.
GE Aerospace: Earnings Week Could Be the Catalyst for $350+
GE Aerospace sits just $36 away from analyst targets at $353, and with earnings dropping April 21st following their monster 26.4% Q4 revenue beat, this could be the breakout catalyst that sends shares soaring past $350.
TSM: The AI King Needs to Clear One More Hurdle
Taiwan Semiconductor (TSM) trades just 5% off its 52-week high with earnings three days away, creating a perfect storm where the AI chip king's undisputed dominance meets a critical timing decision that could make or break your entry point.
IRTC: Cardiac Monitor King Trading at a Discount After Earnings Overreaction
iRhythm Technologies (IRTC) crushed earnings but got unfairly punished by the market, creating a compelling buying opportunity for the cardiac monitoring leader trading 46% below its 52-week high just 17 days before its next earnings report.
DigitalOcean Breaks Out After Crossing $1B Revenue Milestone
DigitalOcean's explosive 150%+ AI customer growth and breakthrough $1B revenue milestone has the stock breaking out of consolidation at the perfect technical setup, making it a compelling buy ahead of earnings season.
TSM: The AI Giant Sitting at a Critical Inflection Point
Taiwan Semiconductor (TSM) sits just 5% from its 52-week high with earnings six days away, but savvy investors should resist the FOMO—this AI powerhouse's stalling momentum and critical technical resistance levels suggest waiting for post-earnings clarity could be the difference between catching a breakout and catching a falling knife.
Crocs Stumbles Despite Earnings Beat — Time to Watch
Despite beating earnings expectations, Crocs (CROX) finds itself in technical limbo with overbought conditions and momentum uncertainty, making it a compelling watchlist candidate as traders await the next directional move.
TSMC: Wait for the Dip Before Riding the AI Wave
Taiwan Semiconductor (TSM) has surged 150% from its October lows but sits just 7% off its 52-week high ahead of next week's earnings, creating a technically extended setup that smart investors should wait to pullback before jumping on the AI semiconductor wave.
EMCOR Is Breaking Out After Record Earnings - Time to Buy
EMCOR Group (EME) is surging on record earnings and a massive $13.25 billion RPO backlog, with the stock breaking out near 52-week highs after a 124% rally—but smart money is just getting started on this industrial powerhouse.
TSM Earnings Could Spark the Next Leg Higher
Taiwan Semiconductor (TSM) is trading just 7% off its 52-week high with 35% earnings growth ahead of April 16th results, potentially setting up a breakout above $390 as AI demand continues to surge.
CareTrust REIT Is Building a Beautiful Story, But Patience Is Key
CareTrust REIT (CTRE) delivered monster 2025 earnings and sits perfectly positioned for healthcare REIT tailwinds, but with the stock trapped in consolidation mode, this compelling growth story requires patience before technical conditions align for a potential breakout.
TSM Is Coiling for a Breakout — Earnings Could Be the Spark
Taiwan Semiconductor (TSM) is trading in a technical sweet spot just days before earnings, sitting 12% below its 52-week high with analyst price targets of $430 suggesting the chip giant could be ready for a major breakout move.
This B. Riley Preferred Share Could Be Setting Up for a Major Move
B. Riley's preferred shares (RILYP) are flashing a compelling setup at $11.25 with a massive 28% dividend yield and 550% recovery from lows, potentially positioning for another major breakout as earnings volatility stabilizes.
TSM Is Coiled for Another AI-Driven Rally
Taiwan Semiconductor (TSM) is coiled at $340 in a tight trading range with earnings just 10 days away, setting up a potential AI-driven breakout that could push shares toward their $390 highs if the chip giant delivers another earnings beat.
Lam Research: Riding the AI Wave with Explosive Earnings Growth
Lam Research (LRCX) is sitting in a technical sweet spot at $219.82 ahead of earnings in 16 days, perfectly positioned to capitalize on exploding AI chip demand that's driving unprecedented growth for this semiconductor equipment giant.
TSM Is Coiling Before Earnings — This Setup Could Explode
Taiwan Semiconductor (TSM) is forming a tight consolidation pattern just 13 days before earnings, setting up what could be an explosive breakout move for the world's most critical chipmaker.
BWXT Rides the Nuclear Renaissance, But Wait for the Pullback
BWX Technologies may be riding the nuclear energy wave with stellar earnings beats, but at $215 per share and a stretched 60x P/E ratio, this 155% winner needs to take a breather before smart money jumps aboard.
DigitalOcean Is Printing Money at $90 — Time to Buy the Dip
While Wall Street chases overpriced AI stocks, DigitalOcean just crushed earnings by 41% and is quietly building a breakout setup just 2% from its 52-week high—making it the perfect contrarian play for savvy investors.
ACADIA Pharma: Beaten-Down Biotech Ready for Liftoff
ACADIA Pharmaceuticals is trading at a 22% discount to its 52-week high with analysts projecting 45% upside potential, making this beaten-down biotech a compelling value play ahead of upcoming earnings.
This Medical Device Stock Is Breaking Out Just Before Earnings
Establishment Labs (ESTA) is breaking out from oversold conditions at $57 with a 32% discount from its 52-week high and an $89 analyst price target, positioning this medical device stock for a potential momentum surge heading into May earnings.
TSM: Earnings Roulette Coming Up in Two Weeks
Taiwan Semiconductor (TSM) finds itself in a precarious position ahead of Q1 2026 earnings on April 16th, trading 13% below its highs with neutral technicals that could swing dramatically based on guidance for AI chip demand and geopolitical developments.
Robinhood's $1.5B Buyback Could Fuel the Next Rally
Robinhood's massive $1.5 billion share buyback authorization following a brutal 54% decline could be the catalyst that transforms this beaten-down fintech from fallen angel to comeback story ahead of earnings in just 28 days.
Taiwan Semi: The Tech Giant That's Moving Too Fast for Its Own Good
TSM's explosive 6.8% rally after Japan's $5.26 billion factory approval might seem like a buying opportunity, but with earnings just 15 days away and the stock still trading 23% below analyst targets, the smart money is waiting for a better entry point.
Drone Stock UMAC: Institutional Buying Surge as Q1 2026 Earnings Approach
**UMAC drone stock plunged 32% despite crushing Q4 earnings by 179%, but with State Street increasing their stake by 698% and analysts maintaining a $24 price target versus today's $12.39 price, this oversold setup could deliver explosive gains ahead of May 7th earnings.**
This Beaten-Down Biotech Could Triple on Alzheimer's Data
**This overlooked biotech trades at a 67% discount with game-changing Alzheimer's trial results due in Q2 that could trigger a massive rebound.**
Marvell Is Building the Backbone of AI Infrastructure
While everyone's chasing Nvidia's AI glory, Marvell Technology is quietly building the essential plumbing that powers the entire AI revolution—and at a 15% discount from recent highs, this infrastructure play is serving up a perfect entry point.
Palantir's Pullback Creates a Rare Entry Opportunity
Palantir's 34% pullback from February highs despite crushing earnings expectations by 7% and guiding for 61% growth in 2026 has created a compelling entry opportunity at $136.69 for investors who missed the initial surge.
EQT Lights Up the Natural Gas Play
Here's a compelling 1-sentence teaser for your blog post: **EQT is crushing earnings with a $3.5 billion free cash flow machine and trading near 52-week highs—discover why this natural gas powerhouse just earned our 63/100 BUY rating as debt evaporates and production soars.**
Mastercard Sits at Crossroads — Oversold Giant Ready for Recovery?
Despite trading near 52-week lows, Mastercard's crushing Q4 earnings and 14% cross-border volume surge suggest this payments giant may be oversold and poised for a recovery that patient investors shouldn't ignore.
Marvell's AI Gold Rush Just Hit a Speed Bump — But the Party's Not Over
Marvell's AI-driven revenue surge to $2.22 billion and data center dominance create a compelling buying opportunity as the stock trades 8% below recent highs despite crushing earnings expectations.
PMN: Why This Alzheimer's Stock is a Value Trap in Disguise
Despite FDA Fast Track status and fresh funding for its Alzheimer's drug trials, ProMIS Neurosciences (PMN) trades 63% below its 52-week high—but our analysis reveals this apparent bargain may actually be a dangerous value trap poised to fall much further.
TSMC: The AI Chip King Coiled for a Breakout
Taiwan Semiconductor (TSM) is trading 16% below its 52-week high despite monster revenue growth, setting up what could be a powerful breakout play ahead of earnings in just 18 days.
BNTX: Oversold Biotech Giant With Leadership Drama Sets Up Potential Bottom
BioNTech's brutal 20.5% plunge on leadership drama and weak guidance has left this cash-rich vaccine giant oversold at $85.68 with a 34.5 RSI, potentially setting up a relief rally for contrarian investors willing to catch a falling biotech knife.
Uranium's Sleeping Giant Awakens: Energy Fuels Delivers Record Production Into a Supply Crunch
Energy Fuels just shattered production expectations while uranium supply deficits explode globally, yet the stock trades 37% below its peak—creating a rare opportunity to buy into a proven producer before the market realizes the uranium shortage isn't coming, it's already here.
BioNTech Could Rally 50% — If You're Patient Enough
German biotech BioNTech just crashed 20% to near 52-week lows after earnings, but this violent selloff might be setting up a patient investor's dream scenario for a potential 50% rally.
Marvel Technology: AI Juggernaut Setting Up for Round Two
**Marvel Technology just delivered a monster earnings beat that crushed every metric, yet the stock sits tantalizingly 5% below its 52-week high—setting up what could be the perfect entry point for the next leg of this AI infrastructure bull run.**
MRVL: AI Chip Giant Primed for Breakout After Record Quarter
Marvell Technology's monster Q4 earnings beat and $6+ billion AI data center revenue run rate make this semiconductor giant a prime breakout candidate as it consolidates near $98 after pulling back from 52-week highs.
EQT's $3.5B Free Cash Flow Monster Is Knocking on Our Door
EQT just crushed earnings by 20% and is building a $3.5 billion free cash flow machine for 2026, trading near 52-week highs while we wait for the perfect pullback to load up on this natural gas powerhouse.
PTGX Is Setting Up for a Major Move — But Wait for the Right Signal
Protagonist Therapeutics (PTGX) is building serious momentum with a 75 momentum score and RSI near 64, positioning itself at a critical inflection point where the right catalyst could trigger a major breakout from its impressive climb off 52-week lows.
Marvell's AI Rocket Gets a Mid-Flight Inspection
Marvell's paradoxical 8.5% drop after crushing earnings with record AI revenue creates a compelling contrarian opportunity for investors willing to bet against the market's tantrum.
This Mining Royalty Play Just Hit Peak Profitability
VMET's explosive 353% Q4 earnings jump has the market sleeping on this mining royalty play that's trading near 52-week lows despite hitting peak profitability.
UMAC: Watching for the Earnings Redemption Story
UMAC plummeted after a brutal 400% earnings miss, but with $103 million in cash and strong revenue growth, this drone stock could be primed for an explosive comeback when May earnings arrive.
Rocket Lab Blasts Off on Record Earnings and $816M Contract Win
Rocket Lab just crushed earnings and secured a massive $816M contract, yet the stock trades 28% below its highs despite guiding for 57% revenue growth—making this aerospace innovator a compelling buy at current levels.
Micron's AI Memory Goldmine Just Hit Overdrive
Micron just delivered the most explosive earnings beat in semiconductor history with 196% revenue growth, proving the AI memory supercycle has officially arrived—and at just 12% off its highs, this cash-printing machine might be your last chance to ride the AI infrastructure goldmine.
Catalyst Pharma: Cash-Rich Rare Disease Player Sitting at a Crossroads
Catalyst Pharma sits on a war chest of $709 million in cash with record earnings and massive buybacks, yet the stock remains stuck at $22.79—making it a compelling watch as key catalysts approach in the next 60 days that could finally unlock this rare disease biotech's breakout potential.
Oil Giant CTRA Just Crushed Revenue and Raised Guidance - Time to Buy the Dip
Coterra Energy's monster 40% revenue beat and raised 2026 guidance has created the perfect storm for contrarian investors, as the market's knee-jerk reaction to a minor EPS miss just handed you a golden entry point at $31.51.
NTLA: This Gene-Editing Pioneer Just Smashed Earnings and FDA Concerns
Intellia Therapeutics (NTLA) just crushed Q4 earnings and cleared a major FDA hurdle, positioning this CRISPR gene-editing pioneer for a potential monster run toward its first drug approval in 2026.
Eli Lilly's Weight Loss Empire Just Crushed Earnings - This Bull Run Has Legs
Eli Lilly just crushed Q4 earnings with its GLP-1 weight loss drugs Mounjaro and Zepbound posting triple-digit growth, and with management projecting another 25% revenue surge in 2026, this pharma giant's obesity treatment dominance is just getting started.